| HOME >> BIOLOGY >> TECHNOLOGY |
- Completion of the production of clinical grade insulin supply for use
in Phase I/II human clinical trials
- Upon FDA approval, initiation of a 30 patient Phase I/II clinical
trial of safflower-produced insulin in the second half of 2008
- Continuation of business development activities toward an insulin
partnership
In 2007, SemBioSys successfully achieved commercial levels of both Apo
AI and Apo AI(Milano) accumulation in safflower. The Company is currently
conducting laboratory testing in an animal model to establish equivalent
functionality in animals of safflower-produced Apo AI(Milano) to the
published values for Apo AI(Milano) that has been successfully used in
human clinical trials. The upcoming milestone events include:
- Completion of in vivo efficacy studies of cholesterol mobilization
with safflower-produced Apo AI(Milano)
- Completion of in vivo efficacy studies of plaque remodeling with
safflower-produced Apo AI(Milano) followed by studies of plaque
regression
- Initiation of a formal partnering process for Apo AI and
Apo AI(Milano) upon receiving the initial in vivo efficacy results
In addition to its pharmaceutical milestones, the Company is also
advancing the development of its non-pharmaceutical products. The upcoming
milestone events expected from these programs include:
- Expansion of the commercial distribution of the Company's personal
care topical oilbody products, specifically Hydresia(TM) and
Hydresia(TM) G2, through Botaneco, including Europe
- Collection of milestone payments from Arcadia Biosciences, Inc., upon
their successful commercial scale-up of High GLA Safflower Oil
- Initiation of pond trials for the Company's shrimp feed additive,
ImmunoSphere(TM)
"During the quarter, we took an important step that should allow
'/>"/>
| SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved |